Disease · HP_0002591
Polyphagia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Polyphagia. Diseases, record HP_0002591. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002591
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Polyphagia
- Open Targets ID
- HP_0002591
- Other names
- Hyperphagia, Voracious appetite
- Highest stage of its drugs
- Phase 3, for 6 of its 8 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs8
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CARBETOCIN | CHEMBL3301668 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SETMELANOTIDE | CHEMBL3301624 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| BELORANIB | CHEMBL4297504 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DENATONIUM ACETATE MONOHYDRATE | CHEMBL5314947 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DIAZOXIDE CHOLINE | CHEMBL4297276 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TOPIRAMATE | CHEMBL220492 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIVOLETIDE | CHEMBL2029605 | Protein | Phase 2/3 | TTD | 1 | 0 | 0 | Drugs and targets |
| OXYTOCIN | CHEMBL395429 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets40
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OXTR | Oxytocin receptor | 2 | Oxytocin receptor agonist | Phase 3 | https://conductscience.org/library/genes/5021 | Drugs and targets |
| CA2 | Carbonic anhydrase 2 | 1 | Carbonic anhydrase II inhibitor | Phase 3 | https://conductscience.org/library/genes/760 | Drugs and targets |
| CA4 | Carbonic anhydrase 4 | 1 | Carbonic anhydrase IV inhibitor | Phase 3 | https://conductscience.org/library/genes/762 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
1 to 10 of 40
See all 40 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03013543 | Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity | Phase 2 | 213 | 2023-08-18 | Genetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency | SETMELANOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03649477 | Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome | Phase 3 | 130 | 2021-11-17 | Prader-Willi Syndrome | CARBETOCIN | Its record names the disease | ClinicalTrials.gov |
| NCT03746522 | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity | Phase 3 | 52 | 2023-12-01 | Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) | SETMELANOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03197662 | Intranasal Oxytocin vs. Placebo for the Treatment of Hyperphagia in Prader-Willi Syndrome | Phase 2 | 32 | 2025-02-07 | Prader-Willi Syndrome, Hyperphagia | OXYTOCIN | Its record names the disease | ClinicalTrials.gov |
| NCT03287960 | Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity | Phase 3 | 15 | 2023-05-23 | Leptin Receptor Deficiency Obesity | SETMELANOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT06173531 | Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | Phase 3 | 175 | Hyperphagia in Prader-Willi Syndrome | CARBETOCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06420297 | OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome | Phase 3 | 168 | Hyperphagia in Prader-Willi Syndrome | CARBETOCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03714373 | Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period | Phase 3 | 115 | Prader-Willi Syndrome | DIAZOXIDE CHOLINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02179151 | Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome | Phase 3 | 108 | Prader-Willi Syndrome, Obesity | BELORANIB | Its record names the disease | ClinicalTrials.gov | |
| NCT02810483 | Study of the Efficacy of Topiramate in Patients With Prader Willi Syndrome Over 8 Weeks | Phase 3 | 69 | Prader-Willi Syndrome | TOPIRAMATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Experimental: Intranasal Oxytocin (IN-OXT) vs Placebo Comparator: Matched Placebo: deaths from any cause | 0 of 15 | 0 of 17 | 32 | NCT03197662 | Trial comparisons |
| Experimental: Intranasal Oxytocin (IN-OXT) vs Placebo Comparator: Matched Placebo: serious adverse events | 0 of 15 | 0 of 17 | 32 | NCT03197662 | Trial comparisons |
Papers from its trials13
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 42821228 | DERIVED | 2 | PubMed |
| 42486751 | DERIVED | 2 | PubMed |
| 41703984 | DERIVED | 1 | PubMed |
| 38671361 | DERIVED | 1 | PubMed |
| 37919617 | DERIVED | 1 | PubMed |
| 36961653 | DERIVED | 2 | PubMed |
| 36647077 | DERIVED | 1 | PubMed |
| 36633570 | DERIVED | 1 | PubMed |
| 36356613 | DERIVED | 1 | PubMed |
| 35112343 | DERIVED | 1 | PubMed |
1 to 10 of 13
See all 13 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002591
GET https://conductscience.org/api/diseases/v1/HP_0002591/targets?page=2